CNCR vs. PSCH

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and PSCH (Invesco S&P SmallCap Health Care ETF) are both Health & Biotech Equities funds - CNCR tracks the Loncar Cancer Immunotherapy Index while PSCH tracks the S&P SmallCap 600 Health Care Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.29%/yr for PSCH.

Performance

CNCR vs. PSCH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Invesco S&P SmallCap Health Care ETF (PSCH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

PSCH

• 1D: -1.23%
• 1M: -1.42%
• YTD: 0.51%
• 6M: -1.51%
• 1Y: 10.38%
• 3Y*: 0.02%
• 5Y*: -5.87%
• 10Y*: 6.67%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. PSCH - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
PSCH Invesco S&P SmallCap Health Care ETF	1.48%

CNCR vs. PSCH - Sectors Allocation Comparison

Sectors	CNCR	PSCH
Healthcare	96.6%	97.3%
Financial Services	3.3%	1.1%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	0.7%
Real Estate	-	-
Technology	-	1.7%
Utilities	-	-

Return for Risk

CNCR vs. PSCH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PSCH

PSCH Risk / Return Rank: 17
PSCH Sharpe Ratio Rank: 17
PSCH Sortino Ratio Rank: 18
PSCH Omega Ratio Rank: 17
PSCH Calmar Ratio Rank: 16
PSCH Martin Ratio Rank: 16

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. PSCH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Invesco S&P SmallCap Health Care ETF (PSCH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	PSCH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.52	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.26	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.28	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.51	—

Drawdowns

CNCR vs. PSCH - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum PSCH drawdown of -46.32%. Use the drawdown chart below to compare losses from any high point for CNCR and PSCH.

Drawdown Indicators

	CNCR	PSCH	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-46.32%	+46.32%
Max Drawdown (1Y) Largest decline over 1 year	—	-15.36%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-22.98%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-46.32%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-46.32%	—
Current Drawdown Current decline from peak	0.00%	-31.47%	+31.47%
Average Drawdown Average peak-to-trough decline	0.00%	-13.45%	+13.45%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	5.54%	—

Volatility

Volatility by Period

	CNCR	PSCH	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	4.01%	—
Volatility (6M) Calculated over the trailing 6-month period	—	14.07%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	20.24%	-20.24%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	22.89%	-22.89%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	23.63%	-23.63%

CNCR vs. PSCH - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than PSCH's 0.29% expense ratio.

Dividends

CNCR vs. PSCH - Dividend Comparison

CNCR has not paid dividends to shareholders, while PSCH's dividend yield for the trailing twelve months is around 0.01%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
PSCH Invesco S&P SmallCap Health Care ETF	0.01%	0.04%	0.27%	0.01%	2.27%	0.00%	0.00%	0.00%	0.00%	0.00%	0.03%

Frequently Asked Questions

Which ETF is better, CNCR or PSCH?

On fees, PSCH is cheaper at 0.29% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or PSCH?

PSCH is cheaper with a 0.29% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or PSCH?

PSCH has the higher dividend yield at 0.01%, compared with 0.00% for CNCR.

What is the main difference between CNCR and PSCH?

CNCR tracks Loncar Cancer Immunotherapy Index, while PSCH tracks S&P SmallCap 600 Health Care Index. They also come from different issuers: Exchange Traded Concepts and Invesco. Their fees differ too: 0.79% for CNCR and 0.29% for PSCH.